Humira is used to treat certain inflammatory conditions. It’s mainly covered by Medicare Part D when self-administered or, more rarely, by Part B when administered by a doctor. Humira ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Do I have MS? What are the early signs of multiple sclerosis? Who should I speak to about my symptoms? We answer your most common questions and worries about multiple sclerosis. Call our free helpline ...

The first symptoms of not eating can include fatigue, difficulty concentrating, and nausea, in part due to hypoglycemia (low blood sugar). As time goes on, more severe symptoms like slurred speech, ...

HIV symptoms vary by the stage of infection, known as primary infection (Stage 1), clinical latency (Stage 2), and AIDS (Stage 3). During primary infection, the symptoms are caused by the virus itself ...

This can help relieve your MS symptoms. It isn’t likely. Hair loss wasn’t a side effect reported in clinical studies of the drug. However, other drugs used to treat MS can cause hair loss ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

Bring your business ideas to life with the tools you need to create and connect—now supercharged with AI and Microsoft 365 Copilot. Reach and exceed your company goals with Microsoft 365. Manage your ...

In addition to inhibiting radiographic progression in patients with PsA, adalimumab resulted in sustained improvement of joint and skin-related symptoms throughout 2 years of treatment. Improvements ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.